(MENAFN- ProactiveInvestors)Abzena's (LON:ABZA) first set of full-year results since listing on the stock market highlight a 'transformational period' for the company says chief executive John Burt. Speaking to Proactive the CEO said the firm is gaining traction with its product mix after generating revenues of £5.7mln in the 12 months to March 31 but will keep looking to expand its portfolio of drug technologies. Abzena listed last July raising £20mln in the process. The company offers expertise as a service to pharma and biotech companies allowing it to generate revenues. Where its IP is then used to modify and improve an antibody it will negotiate a licence agreement. This might entitle the company to milestone payments and ultimately a royalty on sales if that treatment makes it to the market.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.